Tissue Regenix Group plc

Equities

TRX

GB00BNTXR104

Advanced Medical Equipment & Technology

Market Closed - London S.E. Other stock markets 11:35:13 2024-04-19 am EDT			5-day change	1st Jan Change
61.5 ^GBX	0.00%		0.00%	+18.27%

Mar. 19	Tissue Regenix annual loss narrows sharply as revenue jumps	AN
Mar. 19	Earnings Flash (TRX.L) TISSUE REGENIX GROUP Reports FY23 Revenue $29.5M	MT

IN BRIEF: Tissue Regenix launches allograft to aid weakened tissue

December 07, 2022 at 10:50 am EST

Tissue Regenix Group PLC - Leeds, England-based medical device company - Launches Vnew Fascia Lata allograft as an additional line extension in dCell division. Says the Vnew Fascia Lata is a soft tissue allograft used to support weakened tissue that can result in stress urinary incontinence, which affects around one-third of adult women at some point in their lives.

Chief Executive Officer Daniel Lee says: "The diversification of our product portfolio will contribute to our market penetration, as well as provide a significant improvement to quality of life for those patients that receive these allografts."

Current stock price: 0.57 pence, down 2.2% on Wednesday in London

12-month change: up 14%

By Xindi Wei, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Tissue Regenix Group plc

Tissue Regenix annual loss narrows sharply as revenue jumps	Mar. 19	AN
Earnings Flash (TRX.L) TISSUE REGENIX GROUP Reports FY23 Revenue $29.5M	Mar. 19	MT
Earnings Flash (TRX.L) TISSUE REGENIX GROUP Posts FY23 Loss $-0.02	Mar. 19	MT
Tissue Regenix Group plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Tissue Regenix ships first allograft products order	Feb. 06	AN
Tissue Regenix Group plc Signs Two New Distributor Agreements for its Allograft Products in Turkey and Ireland	Feb. 06	CI
Treatt revenue falls; Secure Trust profit picks up	Jan. 25	AN
Solid State expects higher annual revenue	23-10-30	AN
Tissue Regenix Inks Distribution Deal for Allograft Products in Spain	23-10-30	MT
Tissue Regenix Gets Regulatory Nod for Irish Logistics Hub	23-10-30	MT
Tissue Regenix Group plc Announces HPRA approval & distribution agreement in Spain	23-10-30	CI
FTSE 100 Closes Down 0.2% Despite Rebound Driven by Energy Stocks	23-09-05	DJ
Sterling Weakens as China Concerns Grow	23-09-05	DJ
Tissue Regenix loss narrows on higher revenue; launches BioRinse	23-09-05	AN
Earnings Flash (TRX.L) TISSUE REGENIX GROUP Posts H1 Revenue $14.1M	23-09-05	MT
Earnings Flash (TRX.L) TISSUE REGENIX GROUP Posts H1 Loss $-0.01	23-09-05	MT
Tissue Regenix Group plc Announces the Launch of its New BioRinse® Product Line for All Sports Medicine Allografts	23-09-05	CI
Tissue Regenix Group plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-05	CI
FTSE 100 Closes Monday Down 0.4% Dragged by Miners	23-07-17	DJ
Beacon sees delays; Churchill China trades in line	23-07-17	AN
UK Finance Chiefs Are More Gloomy About Outlook	23-07-17	DJ
Tissue Regenix signs exclusive distribution deal with Joint Operations	23-07-10	AN
Tissue Regenix Signs Exclusive Distribution Agreement with Joint Operations Ltd	23-07-10	CI
Tissue Regenix signs multi-year distribution contract	23-05-25	AN
Tissue Regenix Group plc Announces Multi-Year Distribution Agreement with Australian Allografts	23-05-25	CI

Chart Tissue Regenix Group plc

Duration

Period

More charts

Company Profile

Tissue Regenix Group plc is a medical device company in regenerative medicine. The principal activity of the Company is the exploitation of platform technologies in the field of bone graft substitutes and soft tissue. It is focused on the development of regenerative products utilizing its two platform technologies, dCELL, addressing soft tissue needs, and BioRinse, providing sterile bone allografts. Its divisions include dCELL, BioRinse and GBM-V. The Company's patented decellularization technology (dCELL) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Its proprietary BioRinse technology platform is primarily utilized to provide sterile tissue prepared in a manner to minimize the negative effects of processing. GBM-V produces tissue preparations for ophthalmology, primarily cornea, using conventional, classical methods.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-04-25 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Tissue Regenix Group plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

	1st Jan change	Capi.
TISSUE REGENIX GROUP PLC	+18.27%	53.76M
VEEVA SYSTEMS INC.	+3.04%	32.01B
PRO MEDICUS LIMITED	+7.44%	6.91B
SECTRA AB	+15.28%	3.67B
EVOLENT HEALTH, INC.	-10.66%	3.36B
OMNICELL, INC.	-26.04%	1.28B
LUNIT INC.	-40.17%	1.02B
SIMULATIONS PLUS, INC.	+0.92%	903M
VERADIGM INC.	-27.55%	818M
B-SOFT CO.,LTD.	-42.60%	802M

Medical Software & Technology Services